Clinical treatment approaches targeting tumor angiogenesis include the anti-VEGF monoclonal antibody bevacizumab, anti-VEGFR2 monoclonal antibody ramucirumab, VEGFR ligand traps (e.g., aflibercept, VEGFR, PDGFR, c-KIT), and multi-target tyrosine kinase inhibitors (e.g., sunitinib and sorafenib) [76,77] (Table 2, Figure 2). Here, VEGFA is linked to neoplasm.